Cargando…

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment

BACKGROUND: Dry powder inhalers (DPIs) are often used in asthma and chronic obstructive pulmonary disease (COPD) therapies. Using the discrete choice experiment (DCE) methodology, this study conducted in France was designed to assess patients’ preferences for different attributes of DPIs. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawken, Natalia, Torvinen, Saku, Neine, Mohamed-Elmoctar, Amri, Ikbel, Toumi, Mondher, Aballéa, Samuel, Plich, Adam, Roche, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501405/ https://www.ncbi.nlm.nih.gov/pubmed/28683805 http://dx.doi.org/10.1186/s12890-017-0439-x

Ejemplares similares

A review of the value of innovation in inhalers for COPD and asthma
por: Virchow, Johann Christian, et al.
Publicado: (2015)

The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
por: Lewis, A., et al.
Publicado: (2016)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients
por: Darbà, Josep, et al.
Publicado: (2015)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes
por: Levy, Mark L., et al.
Publicado: (2019)

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients
por: Muduma, Gorden, et al.
Publicado: (2016)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment
por: Tervonen, Tommi, et al.
Publicado: (2020)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler)
por: Sandler, Niklas, et al.
Publicado: (2016)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Developing attributes and attribute-levels for a discrete choice experiment on micro health insurance in rural Malawi
por: Abiiro, Gilbert Abotisem, et al.
Publicado: (2014)

Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD
por: Svedsater, Henrik, et al.
Publicado: (2013)

Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance
por: Darbà, Josep, et al.
Publicado: (2016)

Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease
por: Løkke, Anders, et al.
Publicado: (2015)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

RETRACTED ARTICLE: Development of attributes and attribute levels for a discrete choice experiment on patients’ and providers’ choice for antiretroviral therapy service in Northwest Ethiopia
por: Belay, Yihalem Abebe, et al.
Publicado: (2023)

Retraction Note: Development of attributes and attribute levels for a discrete choice experiment on patients’ and providers’ choice for antiretroviral therapy service in Northwest Ethiopia
por: Belay, Yihalem Abebe, et al.
Publicado: (2023)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Using discrete choice experiments to measure preferences for hard to observe choice attributes to inform health policy decisions
por: van den Broek-Altenburg, Eline, et al.
Publicado: (2020)

Attribute nonattendance in COVID‐19 vaccine choice: A discrete choice experiment based on Chinese public preference
por: Xiao, Jianhong, et al.
Publicado: (2022)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rsk539areq4lbcnd2dokobk3rg